Article
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JNCCN - 6 Jan 2021
Pollyea Daniel A, Bixby Dale, Perl Alexander, Bhatt Vijaya Raj, Altman Jessica K, Appelbaum Frederick R, de Lima Marcos, Fathi Amir T, Foran James M, Gojo Ivana, Hall Aric C, Jacoby Meagan, Lancet Jeffrey, Mannis Gabriel, Marcucci Guido, Martin Michael G, Mims Alice, Neff Jadee, Nejati Reza, Olin Rebecca, Percival Mary-Elizabeth, Prebet Thomas, Przespolewski Amanda, Rao Dinesh, Ravandi-Kashani Farhad, Shami Paul J, Stone Richard M, Strickland Stephen A, Sweet Kendra, Vachhani Pankit, Wieduwilt Matthew, Gregory Kristina M, Ogba Ndiya, Tallman Martin S
Abstract excerpt
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates...
Topics
- Adult
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Prognosis